Last reviewed · How we verify

Herceptin — Competitive Intelligence Brief

Herceptin (Trastuzumab-Qyyp) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HER2/neu receptor antagonist monoclonal antibody. Area: Oncology.

marketed HER2/neu receptor antagonist monoclonal antibody HER2 (c-erbB2) proto-oncogene transmembrane receptor protein Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Herceptin (Trastuzumab-Qyyp) — Roche. Trastuzumab inhibits proliferation of HER2-overexpressing tumor cells and mediates antibody-dependent cellular cytotoxicity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Herceptin TARGET Trastuzumab-Qyyp Roche marketed HER2/neu receptor antagonist monoclonal antibody HER2 (c-erbB2) proto-oncogene transmembrane receptor protein 1998-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HER2/neu receptor antagonist monoclonal antibody class)

  1. Roche · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Herceptin — Competitive Intelligence Brief. https://druglandscape.com/ci/trazimera. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: